Web Images Videos Maps News Shopping Gmail more »
Sign in
Scholar Home  
  Advanced Scholar Search
Scholar Preferences
Scholar Results 1 - 10 of about 99 citing Pospisilik: Long-term treatment with dipeptidyl peptidase IV inhibitor improves hepatic and.... (0.14 sec) 

Enhancing incretin action for the treatment of type 2 diabetes

- diabetesjournals.org
DJ Drucker - Diabetes Care, 2003 - Am Diabetes Assoc
RESULTS—Glucagon-like peptide 1 (GLP-1) and glucose-dependent insulinotropic peptide
(GIP) exert important effects on β-cells to stimulate glucose-dependent insulin secretion. Both
peptides also regulate β-cell proliferation and cytoprotection. GLP-1, but not GIP, inhibits ...
Cited by 284 - Related articles - All 13 versions

Improved meal-related β-cell function and insulin sensitivity by the dipeptidyl …


B Ahrén, G Pacini, JE Foley, A Schweizer - Diabetes Care, 2005 - Am Diabetes Assoc
RESULTS—In subjects completing 52 weeks with participation in all meal tests (n = 57), HbA
1c (A1C) decreased in the vildagliptin/metformin group (VM group, n = 31) but increased in the
placebo/metformin group (PM group, n = 26; between-group difference −1.0 ± 0.2%; P < ...
Cited by 178 - Related articles - BL Direct - All 9 versions

Dipeptidyl peptidase IV inhibitor treatment stimulates β-cell survival and islet …

- diabetesjournals.org
JA Pospisilik, J Martin, T Doty, JA Ehses, N Pamir, FC … - Diabetes, 2003 - Am Diabetes Assoc
Recent studies into the physiology of the incretins glucose-dependent insulinotropic polypeptide
(GIP) and glucagon-like peptide-1 (GLP-1) have added stimulation of β-cell growth,
differentiation, and cell survival to well-documented, potent insulinotropic effects. ...
Cited by 163 - Related articles - BL Direct - All 4 versions

Therapeutic strategies based on glucagon-like peptide 1

- diabetesjournals.org
CF Deacon - Diabetes, 2004 - Am Diabetes Assoc
Glucagon-like peptide (GLP)-1 is an incretin hormone with potent glucose-dependent insulinotropic
and glucagonostatic actions, trophic effects on the pancreatic β-cells, and inhibitory effects on
gastrointestinal secretion and motility, which combine to lower plasma glucose and ...
Cited by 155 - Related articles - BL Direct - All 5 versions

Therapeutic potential of dipeptidyl peptidase IV inhibitors for the treatment of type 2 …


DJ Drucker - eid, 2003 - informahealthcare.com
Incretins are peptide hormones, exemplified by glucose-dependent insulino- tropic peptide and
glucagon-like peptide 1 that are released from the gut in response to nutrient ingestion and enhance
glucose-stimulated insulin secre- tion. Incretin action is terminated due to N-terminal ...
Cited by 118 - Related articles - All 6 versions

The crystal structure of dipeptidyl peptidase IV (CD26) reveals its functional …

- nih.gov
M Engel, T Hoffmann, L Wagner, M … - Proceedings of the …, 2003 - National Acad Sciences
The membrane-bound glycoprotein dipeptidyl peptidase IV (DP IV, CD26) is a unique multifunctional
protein, acting as receptor, binding and proteolytic molecule. We have determined the sequence
and 1.8 Å crystal structure of native DP IV prepared from porcine kidney. The crystal ...
Cited by 105 - Related articles - All 10 versions

Inhibitors of dipeptidyl peptidase IV: a novel approach for the prevention and …


CF Deacon, B Ahrén, JJ Holst - eid, 2004 - informahealthcare.com
Inhibitors of the enzyme dipeptidyl peptidase IV (DPP IV) are of increasing interest to both diabetologists
and the pharmaceutical industry alike, as they may become established as the next member
of the oral antidiabetic class of therapeutic agents, designed to lower blood glucose and, ...
Cited by 102 - Related articles - All 7 versions

Prolyl peptidases: a serine protease subfamily with high potential for drug …

- activx.com [PDF] 
JS Rosenblum, JW Kozarich - Current opinion in chemical biology, 2003 - Elsevier
Much attention has recently been given to a class of proteases that cleave proteins and peptides
after proline residues. This class includes dipeptidyl peptidase IV (DPP IV; also termed
CD26), fibroblast activation protein α (FAP; seprase), DPP7 (DPP II; quiescent cell proline ...
Cited by 94 - Related articles - All 5 versions

Type 2 diabetes—therapy with dipeptidyl peptidase IV inhibitors


HU Demuth, CHS McIntosh, RA Pederson - BBA-Proteins and Proteomics, 2005 - Elsevier
This was demonstrated in rat applying the specific DP IV inhibitor isoleucyl thiazolidine. It was
published in 1996 for the first time that a specific DP IV inhibitor in a given dose was able to completely
block glucagon-like peptide-1 (GLP-1) degradation in vivo resulting in improved insulin ...
Cited by 79 - Related articles - All 3 versions

Therapeutic approaches to preserve islet mass in type 2 diabetes

- tufts.edu [PDF] 
LL Baggio, DJ Drucker - 2006 - Annual Reviews
Type 2 diabetes is characterized by hyperglycemia resulting from insulin resistance in the setting
of inadequate β-cell compensation. Currently available therapeutic agents lower blood glucose
through multiple mechanisms but do not directly reverse the decline in β-cell mass. ...
Cited by 78 - Related articles - BL Direct - All 10 versions


Result Page: 

1

2

3

4

5

6

7

8

9

10

Next


 


Go to Google Home - About Google - About Google Scholar

©2009 Google